Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that GLP-1 receptors and proglucagon are expressed in the skin of newborn mice, with GLP-1 potentially playing a role in skin development and hair follicle formation.

GLP-1 RA medications may be linked to hair loss.

In this case study, a man with necrolytic migratory erythema and a glucagonoma experienced decreased plasma glucagon levels and reduced metastases after treatment with dimethyltriazenoimidazole carboxamide.

This literature review highlights a potential but uncertain link between GLP-1 receptor agonist therapy for type 2 diabetes and obesity and hair loss, with variations among different medications.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.

This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

This case report documents a cat with necrolytic migratory erythema due to glucagonoma and diabetes mellitus, highlighting similarities to glucagonoma syndrome in humans.

In this study, GLP-1 receptor agonists reduced BMI and improved metabolic and reproductive outcomes in women with PCOS, though the long-term effects remain unclear.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

This review discusses various skin diseases with endocrinological origins and reports no clinical results, highlighting the need for interdisciplinary understanding in diagnosis.

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.

This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.

This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.

This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.